Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2013 2
2014 3
2015 4
2016 3
2017 5
2018 1
2019 4
2020 11
2021 28
2022 17
2023 17
2024 27
2025 23
2026 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers.
Yoo C, Fabregat-Franco C, Lin CC, Qvortrup C, Oh DY, Yau T, Kim HD, Castet F, Ponz Sarvise M, Hsu C, Rohrberg KS, Lichtenegger FS, Franjkovic I, Kratochwil NA, Bessa J, Rossmann E, Schwalie PC, Rieder N, Pöschinger T, Sie CG, Dettling S, Schlenker R, Jiang T, Dai C, Yun H, Hall E, Yeo Te-Ying A, Hoves S, Cannarile MA, Schiff C, Sangro B. Yoo C, et al. Among authors: kim hd. J Immunother Cancer. 2026 Mar 9;14(3):e012783. doi: 10.1136/jitc-2025-012783. J Immunother Cancer. 2026. PMID: 41802810 Free PMC article. Clinical Trial.
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.
Schram AM, Park JJ, Italiano A, Kitano S, Guo Y, Li J, Bedard PL, van Marcke C, Ko R, Lunger L, Klotz DM, Hussain J, Maier D, Erzen D, Planchard D, Prenen H, Clay TD, Park JO, Kim HD, Hernando-Calvo A, Maruki Y, Ponz-Sarvise M, Dumbrava E. Schram AM, et al. Among authors: kim hd. Future Oncol. 2026 Mar;22(7):795-803. doi: 10.1080/14796694.2026.2637740. Epub 2026 Mar 4. Future Oncol. 2026. PMID: 41777164 Free PMC article.
Integrative Multiomic Classification Reveals Distinct Origins and Evolutionary Trajectories of Thymic Epithelial Tumors.
Park S, Yi K, Lee J, Yang MJ, Song JH, Lim J, Kim T, Kim S, Kim SY, Kim HD, Kim YH, Lee SB, Jung YJ, Park H, Lee JJ, An Y, Youk J, Na KJ, Park S, Lee HJ, Park IK, Kang CH, Shin EC, Kim TM, Heo WD, Lee C, Koh GY, Cho SY, Ju YS, Kim YT. Park S, et al. Among authors: kim hd. Cancer Res. 2026 Mar 16;86(6):1496-1513. doi: 10.1158/0008-5472.CAN-24-4977. Cancer Res. 2026. PMID: 41671387 Free PMC article.
Zolbetuximab Plus Chemotherapy as First-Line Treatment in Patients with Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: Korean Population Subgroup-Combined Efficacy and Safety Analysis from SPOTLIGHT and GLOW.
Lee KW, Oh SC, Kim JG, Sym SJ, Shim BY, Kang SY, Kim IH, Kim JH, Chon HJ, Cho SH, Song EK, Oh DY, Kim JS, Park YI, Kang WK, Kim HD, Lee J, Yi M, Ryu MH. Lee KW, et al. Among authors: kim hd. Cancer Res Treat. 2025 Dec 5. doi: 10.4143/crt.2025.935. Online ahead of print. Cancer Res Treat. 2025. PMID: 41381060 Free article.
128 results